The antitumor efficiency and clinical translation of traditional nanomedicines is mainly
restricted by low drug loading, complex preparation technology, and potential toxicity …

The last decade witnessed the great advances in the development of nanomedicines. As a
kind of attractive nanomedicine, carrier-free nanomedicines received extensive …

Covalent modification of therapeutic compounds is a clinically proven strategy to devise
prodrugs with enhanced treatment efficacies. This prodrug strategy relies on the modified …

Lipid–drug conjugates (LDCs) are drug molecules that have been covalently modified with
lipids. The conjugation of lipids to drug molecules increases lipophilicity and also changes …

This article provides a broad spectrum about the nanoprodrug fabrication advances co‐
driven by prodrug and nanotechnology development to potentiate cancer treatment. The …

Clinical applications of many anti-cancer drugs are restricted due to their hydrophobic
nature, requiring use of harmful organic solvents for administration, and poor selectivity and …

Despite the rapid developments in nanotechnology and biomaterials, the efficient delivery of
chemotherapeutic agents is still challenging. Prodrug-based nanoassemblies have many …

This review aims to highlight the development of novel vitamin E conjugates for the
vectorization of active pharmaceutical ingredients through nanotechnologies. The physico …

Currently, a majority of cancer treatment strategies are based on the removal of tumor mass
mainly by surgery. Chemical and physical treatments such as chemo-and radiotherapies …

For four decades, liposomes composed of both naturally occurring and synthetic lipids have
been investigated as delivery vehicles for low molecular weight and macromolecular drugs …